Business Wire 17-Apr-2018 4:01 PM
Sage Therapeutics (NASDAQ:SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v. formulation of brexanolone for the treatment of postpartum depression (PPD) as well as SAGE-217, its novel, next-generation positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, in major depressive disorder (MDD), will be presented in podium and poster sessions at the following upcoming medical meetings:
North American Society for Psychosocial Obstetrics and Gynecology (NASPOG)2018 Biennial Meeting, April 20-22, 2018 in Philadelphia
American College of Obstetricians and Gynecologists (ACOG)2018 Annual Clinical and Scientific Meeting, April 27-30, 2018 in Austin, Texas
American Psychiatric Association (APA)2018 Annual Meeting, May 5-9, 2018 in New York
Society of Biological Psychiatry (SOBP)73rd Annual Meeting, May 10-12, 2018 in New York
About Sage TherapeuticsSage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed Phase 3 clinical development for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.
Limited Time Offer:
Claim your free copy of income expert Bryan Perry's new report:
My Top Monthly Dividend Payer (8% Dividend Yield)
You'll also receive Bryan Perry's weekly e-letter, Dividend Investing Weekly, at no cost, along with other associated financial content and special offers.